[1]
Simon F, Javelle E, Oliver M, Leparc-Goffart I, Marimoutou C. Chikungunya virus infection. Curr Infect Dis Rep 2011; 13(3): 218-28.
[2]
Cunha RVD, Trinta KS. Chikungunya virus: clinical aspects and treatment - A Review. Mem Inst Oswaldo Cruz 2017; 112(8): 523-31.
[3]
Fritel X, Rollot O, Gérardin P, et al. Chikungunya virus infection during pregnancy, Reunion, France, 2006. Emerg Infect Dis 2010; 16(3): 418-25.
[5]
Grivard P, Le Roux K, Laurent P, et al. Molecular and serological diagnosis of Chikungunya virus infection. Pathol Biol 2007; 55(10): 490-4.
[6]
Weaver SC, Osorio JE, Livengood JA, Chen R, Stinchcomb DT. Chikungunya virus and prospects for a vaccine. Expert Rev Vaccines 2012; 11(9): 1087-101.
[7]
Mallilankaraman K, Shedlock DJ, Bao H, et al. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis 2011; 5(1): e928.
[8]
Agnandji ST, Lell B, Soulanoudjingar SS, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011; 365(20): 1863-75.
[9]
Elliott SL, Suhrbier A, Miles JJ, et al. Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol 2008; 82(3): 1448-57.
[10]
Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater 2013; 12(11): 967-77.
[11]
Dhanda SK, Chaudhary K, Gupta S, Brahmachari SK, Raghava GP. A web-based resource for designing therapeutics against Ebola Virus. Sci Rep 2016; 6: 24782.
[12]
Wittrup A, Lieberman J. Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet 2015; 16(9): 543-52.
[13]
Broderick JA, Zamore PD. MicroRNA therapeutics. Gene Ther 2011; 18(12): 1104-10.
[14]
Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 2016; 44(D1): D7-D19.
[15]
Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Wheeler DL. GenBank. Nucleic Acids Res 2008; 36(Database issue): D25-30.
[16]
Rose PW, Bi C, Bluhm WF, et al. The RCSB Protein Data Bank: new resources for research and education. Nucleic Acids Res 2013; 41(Database issue): D475-82.
[17]
Grant JR, Stothard P. The CGView Server: a comparative genomics tool for circular genomes. Nucleic Acids Res 2008; 36(Web Server issue): W181-4.
[18]
Stothard P, Wishart DS. Circular genome visualization and exploration using CGView. Bioinformatics 2005; 21(4): 537-9.
[19]
Chenna R, Sugawara H, Koike T, et al. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 2003; 31(13): 3497-500.
[20]
Kumar S, Stecher G, Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. Mol Biol Evol 2016; 33(7): 1870-4.
[21]
Behura SK, Severson DW. Comparative analysis of codon usage bias and codon context patterns between dipteran and hymenopteran sequenced genomes. PLoS One 2012; 7(8): e43111.
[23]
Olson SA. EMBOSS opens up sequence analysis. European Molecular Biology Open Software Suite. Brief Bioinform 2002; 3(1): 87-91.
[24]
Pinheiro M, Afreixo V, Moura G, Freitas A, Santos MA, Oliveira JL. Statistical, computational and visualization methodologies to unveil gene primary structure features. Methods Inf Med 2006; 45(2): 163-8.
[25]
Hansen JE, Lund O, Tolstrup N, Gooley AA, Williams KL, Brunak S. NetOglyc: prediction of mucin type O-glycosylation sites based on sequence context and surface accessibility. Glycoconj J 1998; 15(2): 115-30.
[26]
Norton PA, Comunale MA, Krakover J, et al. N-linked glycosylation of the liver cancer biomarker GP73. J Cell Biochem 2008; 104(1): 136-49.
[27]
Li W, Godzik A. Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences. Bioinformatics 2006; 22(13): 1658-9.
[28]
Huang WL, Tsai MJ, Hsu KT, Wang JR, Chen YH, Ho SY. Prediction of linear B-cell epitopes of hepatitis C virus for vaccine development. BMC Med Genomics 2015; 8(Suppl. 4): S3.
[29]
Zheng W, Zhang C, Hanlon M, Ruan J, Gao J. An ensemble method for prediction of conformational B-cell epitopes from antigen sequences. Comput Biol Chem 2014; 49: 51-8.
[30]
Zhang Q, Wang P, Kim Y, et al. Immune epitope database analysis resource (IEDB-AR). Nucleic Acids Res 2008; 36(Web Server issue): W513-8.
[31]
Singh H, Raghava GPS. ProPred1: prediction of promiscuous MHC Class-I binding sites. Bioinformatics 2003; 19(8): 1009-14.
[32]
Nielsen M, Lund O, Buus S, Lundegaard C. MHC class II epitope predictive algorithms. Immunology 2010; 130(3): 319-28.
[33]
Qureshi A, Thakur N, Kumar M. VIRsiRNApred: a web server for predicting inhibition efficacy of siRNAs targeting human viruses. J Transl Med 2013; 11: 305.
[34]
Chaudhary K, Nagpal G, Dhanda SK, Raghava GP. Prediction of Immunomodulatory potential of an RNA sequence for designing non-toxic siRNAs and RNA-based vaccine adjuvants. Sci Rep 2016; 6: 20678.
[35]
Nam JW, Shin KR, Han J, Lee Y, Kim VN, Zhang BT. Human microRNA prediction through a probabilistic co-learning model of sequence and structure. Nucleic Acids Res 2005; 33(11): 3570-81.
[36]
Liu X, He S, Skogerbø G, Gong F, Chen R. Integrated sequence-structure motifs suffice to identify microRNA precursors. PLoS One 2012; 7(3): e32797.
[37]
Hofacker IL. Vienna RNA secondary structure server. Nucleic Acids Res 2003; 31(13): 3429-31.
[38]
Larsen F, Gundersen G, Lopez R, Prydz H. CpG islands as gene markers in the human genome. Genomics 1992; 13(4): 1095-107.